Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25584146 | 0.83 | CYP11B2 (0.47) | CYP11B2PTGS2 | |
| SCHEMBL25584201 | 0.71 | CYP11B2 (0.55) | CYP11B2CYP11B1 | |
| SCHEMBL25584444 | 0.71 | CYP11B2 (0.46) | CYP11B2MAOAMAOBPTGS2 | |
| SCHEMBL25584168 | 0.66 | CYP11B2 (0.49) | CYP11B2CYP11B1 | |
| SCHEMBL25584114 | 0.64 | CYP11B2 (0.50) | CYP11B2CYP11B1 | |
| SCHEMBL19012368 | 0.64 | MAPT (0.43) | — | |
| SCHEMBL31307575 | 0.64 | CYP11B2 (0.69) | CYP11B2CYP11B1 | |
| SCHEMBL19012622 | 0.64 | MAPT (0.43) | — | |
| SCHEMBL25584589 | 0.64 | CYP11B2 (0.51) | CYP11B2PTGS2 | |
| SCHEMBL14660566 | 0.62 | MAOA (0.47) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181538-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181538-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | SLC5A2, SLC5A1, REN | CYP11B2 10/4885MAOA 1627/4885MAOB 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.